BioSpace News Archive

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), today announced that several abstracts relating to the Secura Bio product COPIKTRA® (duvelisib) will be presented at the 63rd annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program.

ESCAPE Bio, Inc., a clinical-stage company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases, today announced Mark Kaufmann has joined as Chief Financial Officer and Chief Business Officer.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today announced that it has completed patient enrollment in its Pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

Applied DNA Sciences, Inc. announced today a development in its cotton genomics program (the “Program”) that the Company believes can bring forensic proof of cotton authenticity and provenance specifically related to regional cotton varietals to give brands and relevant regulatory authorities access to fiber origin data regardless of location of manufacture.

GlycoMimetics, Inc. (Nasdaq: GLYC), announced today that the National Cancer Institute (NCI), have completed enrollment of 267 patients in the Phase 2 portion of the adaptive Phase 2/3 trial evaluating whether uproleselan improves overall survival in newly diagnosed patients 60 years or older with acute myeloid leukemia (AML).

Mr. Ko’s presentation will be available on demand beginning on December 6, 2021 at 7:00 a.m. ET. Please visit here to learn more about the event and to register.

Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today it has entered into an agreement with Thermo Fisher Scientific to manufacture molnupiravir, Merck’s investigational oral antiviral medicine for the treatment of COVID-19.

bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how bioAffinity successfully uses RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells at Cell Bio.